Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-versus-Host Disease

Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants

Bone Marrow Transplantation volume 41, pages 651–658 (2008)Cite this article

Abstract

The utility of GVHD prophylaxis with cyclosporin, MTX and prednisolone (CSA/MTX/Pred) in allogeneic PBPC transplants is not well described although there are published data using this combination after bone marrow transplants. The effectiveness of this regimen on the prevention of GVHD was assessed in 107 consecutive sibling and less-than-ideal donor transplant recipients over a 5-year period and compared to that observed in 65 patients receiving standard CSA and short-course MTX without prednisolone. Oral prednisolone was commenced on day +14 at 0.5 mg/kg per day, increased to 1 mg/kg per day on day +21 to day +34 then gradually tapered and ceased by day +100. The cumulative incidence of acute GVHD (grades II–IV) to day 100 in those receiving prednisolone prophylaxis was lower (52 versus 76%, P<0.01). The onset of symptomatic GVHD requiring systemic treatment was delayed from a median of 41 days post transplant to 92 days. When assessment of the cumulative incidence of symptomatic GVHD continued to day +180 incidence became similar (74 versus 78%), there was no difference between the two groups in rates of relapse, transplant-related mortality, infections or chronic GVHD. We conclude that the addition of prednisolone to CSA/MTX delays the onset of early acute GVHD in PBPC recipients but has no impact on the overall incidence of GVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Chao NJ, Chen BJ . Prophylaxis and treatment of acute graft versus host disease. Semin Hematol 2006; 43: 32–41.

    Article  CAS  PubMed  Google Scholar 

  2. Lazarus HM, Vogelsang GB, Rowe JM . Prevention and treatment of acute graft-versus host-disease: the old and the new. A report from the Eastern Cooperative Oncology group (ECOG). Bone Marrow Transplant 1997; 19: 577–600.

    Article  CAS  PubMed  Google Scholar 

  3. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AW et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.

    CAS  PubMed  Google Scholar 

  4. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181.

    Article  CAS  PubMed  Google Scholar 

  5. Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E . Cyclosporine, methotrexate and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host-disease in bone marrow transplantation from HLA-identical sibling donors: a prospective randomized study. Blood 2000; 96: 2391–2398.

    CAS  PubMed  Google Scholar 

  6. Atkinson K, Biggs J, Concannon A, Dodds A, Young S, Wilson F et al. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy. Aust NZ J Med 1991; 21: 850–856.

    Article  CAS  Google Scholar 

  7. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD et al. Cyclosporine, methotrexate and prednisone compared with cyclosporine and prednisolone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225–1230.

    Article  CAS  PubMed  Google Scholar 

  8. Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant 2000; 6: 254–261.

    Article  CAS  PubMed  Google Scholar 

  9. Ross M, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD et al. Cyclosporine, methotrexate and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs-host disease: effect on chronic graft-vs-host disease and long-term survival. Biol Blood Marrow Transplant 1999; 5: 285–291.

    Article  CAS  PubMed  Google Scholar 

  10. Storb R, Pepe M, Anasetti C, Appelbaum FR, Beatty P, Doney K et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990; 76: 1037–1045.

    CAS  PubMed  Google Scholar 

  11. Ancín I, Ferrá C, Gallardo D, Peris J, Berlanga J, Gonzalez JR et al. Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT? Bone Marrow Transplant 2001; 28: 39–45.

    Article  PubMed  Google Scholar 

  12. Funke VM, Setubal DC, Ruiz J, Lima DH, Bonfim CM, Bitencourt MA et al. Low incidence of acute graft versus host disease and reduced early mortality in CP-CML patients transplanted using CSA, MTX and MP as immunoprophylaxis. Biol Blood Marrow Transplant 2006; 12 (Suppl 1): 2 (abstract 84).

    Google Scholar 

  13. Quellmann S, Bohlius J, Huebel K, Schwarzer G, Engert A . Corticosteroids for preventing graft-versus-host disease after myeloablative stem cell transplantation: a comprehensive meta-analysis. Haematologica 2006; 91: S1 (abstract 0302).

    Google Scholar 

  14. Remberger M, Ringdén O, Blau I-W, Ottinger H, Kremens B, Kiehl MG et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98: 1739–1745.

    Article  CAS  PubMed  Google Scholar 

  15. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000; 95: 3702–3709.

    CAS  PubMed  Google Scholar 

  16. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074–5087.

    Article  Google Scholar 

  17. Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100: 761–767.

    Article  CAS  PubMed  Google Scholar 

  18. Flowers MED, Parker PM, Johnston LJ, Matos AVB, Storer B, Bensinger WI et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long term follow up of a randomized trial. Blood 2002; 100: 415–419.

    Article  CAS  PubMed  Google Scholar 

  19. Grigg AP, Gibson J, Bardy PG, Reynolds J, Shuttleworth P, Koelmeyer RL et al. A prospective multicenter trial of peripheral blood stem cell allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclosphosphamide reduced intensity conditioning. Biol Blood Marrow Transplant 2007; 13: 560–567.

    Article  CAS  PubMed  Google Scholar 

  20. Ritchie DS, Morton J, Szer J, Roberts AW, Durrant S, Shuttleworth P et al. Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2003; 9: 435–442.

    Article  CAS  PubMed  Google Scholar 

  21. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 10: 295–304.

    Article  Google Scholar 

  22. Filipovich AH, Weisdorf D, Pavletic S, Socié G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–955.

    Article  PubMed  Google Scholar 

  23. Szer J, Durrant S, Schwarer AP, Bradstock KF, Gibson J, Arthur C et al. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation. Intern Med J 2004; 34: 98–101.

    Article  CAS  PubMed  Google Scholar 

  24. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.

    Article  CAS  PubMed  Google Scholar 

  25. Grigg AP, Shuttleworth P, Reynolds J, Schwarer AP, Szer J, Bradstock K et al. Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2006; 91: 3835–3843.

    Article  CAS  PubMed  Google Scholar 

  26. Leelasiri A, Greer JP, Stein RS, Goodman S, Brandt SA, Edwards JR et al. Graft-versus-host disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone. Bone Marrow Transplant 1995; 15: 401–405.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Haematology & BMT service, The Royal Melbourne Hospital, Parkville, Victoria, Australia

    R Hoyt, D S Ritchie, A W Roberts, D J Curtis, J Szer & A P Grigg

  2. Clinical Epidemiology and Health Services Evaluation Unit, Royal Melbourne Hospital, Parkville, Victoria, Australia

    L MacGregor

Authors
  1. R Hoyt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D S Ritchie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A W Roberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L MacGregor
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D J Curtis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Szer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A P Grigg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Hoyt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoyt, R., Ritchie, D., Roberts, A. et al. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. Bone Marrow Transplant 41, 651–658 (2008). https://doi.org/10.1038/sj.bmt.1705955

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705955

Keywords

This article is cited by

Search

Advanced search

Quick links